Combination Approaches with Immune-Checkpoint Blockade in Bladder Cancer - Matthew Galsky

Matthew Galsky and Alicia Morgans share in a discussion on combination and maintenance strategies for muscle-invasive and metastatic bladder cancer and a number of reasons for combining immunotherapy with immune checkpoint blockade. These reasons include the concept of immunogenic cell death, depletion of suppressive immune cell subsets and independent drug action. 


Matthew Galsky, MD, Director, Genitourinary Medical Oncology and Associate Medical Director at theCancer Clinical Trials Office at Mount Sinai Health System and The Tisch Cancer Institute 

Alicia Morgans, MD, MPH Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.